Lyra Therapeutics enters $50M at-the-market equity offering with Cantor Fitzgerald

Lyra Therapeutics, Inc.

Enters Controlled Equity Offering Sales Agreement to sell up to $50.0M of common stock through Cantor Fitzgerald.
Shares sold in at-the-market offerings; Cantor receives 3.0% commission on gross proceeds.
Company has no obligation to sell any shares and may suspend or terminate offering at any time.
Offering registered under existing S-3 shelf; prospectus supplement filed September 1, 2023.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Lyra Therapeutics, Inc. entered into Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. valued at $50.0 million (effective 2023-09-01).

Action: entry
Agreement: atm program
Counterparty: Cantor Fitzgerald & Co.
Value: $50.0 million
Effective: 2023-09-01

Exact text from the filing

On September 1, 2023, Lyra Therapeutics, Inc. (the “Company”) entered into a Controlled Equity Offering SM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor”) pursuant to which the Company may offer and sell, from time to time through Cantor, shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), for aggregate gross proceeds of up to $50.0 million (the “Shares”).

View on SEC.gov

119 material agreements filed in the last 30 days. Browse all material agreements →

Lyra Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-227626

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.